- Kraig Biocraft Laboratories (OTCQB: KBLB) secures four U.S. trademarks for SpydaSilk® brand, positioning for global luxury market.
- The company achieves a breakthrough with the largest DNA construct for scalable spider silk production.
- The latest BAM-1 production is set to surpass the entire 2024 output, marking significant operational expansion.
Kraig Biocraft Laboratories (OTCQB: KBLB) has taken substantial steps in commercializing spider silk with the acquisition of four registered U.S. trademarks for its SpydaSilk® brand. This strategic move aims to cement its presence in the global luxury performance apparel and textile markets.
The company's synthetic biology team has developed what is believed to be the world's largest DNA construct dedicated to spider silk production. This innovation enables the engineering of silkworms that can produce robust fibers with higher yields, paving the way for larger-scale operations.
KBLB's recent BAM-1 production run has achieved a milestone by potentially surpassing its total anticipated 2024 output, showcasing the company's readiness to meet increasing market demands. This development reflects KBLB's expanding infrastructure and capacity.
In Southeast Asia, KBLB has strengthened its foothold in Vietnam with substantial government support, establishing partnerships within the region's prominent textile corridor. This expansion positions the company strategically for growth in Asia.
Additionally, KBLB's spider silk technology is garnering interest from energy and defense industries. The material's potential applications in ballistic armor, aerospace, and energy-efficient solutions highlight its cross-sector appeal and transformative potential.
